Business
Stonegate Capital Partners Initiates Coverage on Resverlogix Corp. (TSX: RVX)
DALLAS, TX / ACCESSWIRE / March 19, 2018 / Resverlogix Corp. (TSX: RVX). COMPANY DESCRIPT...
About this update from Resverlogix Corp.
[{"type":"text","content":"Stonegate Capital Partners Initiates Coverage on Resverlogix Corp. (TSX: RVX)DALLAS, TX / ACCESSWIRE / March 19, 2018 / Resverlogix Corp. (TSX: RVX).\nCOMPANY DESCRIPTION\nResverlogix Corp., based in Calgary, Canada, and San Francisco, CA, is in the advanced clinical stages of developing its lead small molecule therapeutic apabetalone (RVX-208). This molecule is a first-in-class (and only) selective Bromodomain and ExtraTerminal domain (\"BET\") inhibitor being used in clinical trials; extensive research has shown that apabetalone can act via an epigenetic mechanism to regulate genes, thereby normalizing gene function, or in essence \"hitting the reset button\". Resverlogix began its BETonMACE Phase 3 clinical study in cardiovascular disease (CVD) patients with diabetes mellitus and low HDL in October 2015, and top line data is expected by the end of 2018. The Company is also investigating the molecule for the treatment of other diseases such as chronic kidney disease (BETonRENAL Phase 2a), and orphan diseases (Phase 2a for Fabry's Disease) based on the results of previous clinical studies.\nSUMMARY\n\n The Company's lead molecule apabetalone, or RVX-208, began a Phase 3 study in October 2015 that has fully enrolled over 2400 patients at an estimated 177 sites globally for high-risk type 2 diabetes patients with CVD (first patient randomized and dosing commenced November 2015); Resverlogix expects to report top-line data this year in Q418\n Within the BETonMACE Phase 3 study, the primary endpoint is the time to first occurrence of MACE; additionally, the trial will test for renal function in a subset population of chronic kidney disease patients as well as assess neurological function with the Montreal Cognitive Assessment (MoCA) in patients over the age of 70\n RVX-208 has demonstrated a strong safety profile with over 1800 patients treated to date in over 19 countries around the world\n Apabetalone's clinical results are on top of current standard of care treatments, with many patients being treated already taking high levels of statins, beta blockers, glucose management drugs and ace inhibitors as a result of prior major adverse cardiovascular events (MACE); clinical trial participants have demonstrated reduced risk for future MACE of 57% (p=.0181) with apabetalone, and it is notable that Resverlogix's current target in its B...